Line 20:
Line 20:
**Symptoms related to excess [[glucocorticoid]]
**Symptoms related to excess [[glucocorticoid]]
**Symptoms related to excess [[mineralocorticoid]]
**Symptoms related to excess [[mineralocorticoid]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* Round and homogeneous density, smooth contour and sharp margination
* Round and homogeneous density, smooth contour and sharp margination
Line 28:
Line 28:
* Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences
* Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences
* [[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]]
* [[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Cortisol level]]
* [[Cortisol level]]
Line 40:
Line 40:
* Symptoms related to excess [[mineralocorticoid]]
* Symptoms related to excess [[mineralocorticoid]]
* Symptoms related to excess [[androgen]] or [[estrogen]] secretion
* Symptoms related to excess [[androgen]] or [[estrogen]] secretion
|
| style="padding: 5px 5px; background: #F5F5F5;" |
*Irregular shape
*Irregular shape
*Inhomogeneous density because of central areas of low attenuation due to [[tumor]] [[necrosis]]
*Inhomogeneous density because of central areas of low attenuation due to [[tumor]] [[necrosis]]
Line 52:
Line 52:
*High standardized uptake value (SUV) on FDG-[[PET scan|PET-CT]] study
*High standardized uptake value (SUV) on FDG-[[PET scan|PET-CT]] study
*Evidence of local invasion or [[Metastasis|metastases]]
*Evidence of local invasion or [[Metastasis|metastases]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Androgen|Adrenal androgens]] [[[DHEAS]]]
* [[Androgen|Adrenal androgens]] [[[DHEAS]]]
* [[Androstenedione]]
* [[Androstenedione]]
Line 62:
Line 62:
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Cushing's syndrome]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Cushing's syndrome]]'''
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* Proximal [[muscle weakness]]
Line 68:
Line 68:
* Excess [[sweating]]
* Excess [[sweating]]
* [[Headache]]
* [[Headache]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* Imaging may show [[mass]] if presents
* Imaging may show [[mass]] if presents
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* 24-hour urine [[cortisol]]
* 24-hour urine [[cortisol]]
* Midnight salivary [[cortisol]]
* Midnight salivary [[cortisol]]
Line 83:
Line 83:
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]].
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]].
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients.
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients.
|[null Insert paragraph]
|style="padding: 5px 5px; background: #F5F5F5;" |[null Insert paragraph]
* Increased attenuation on nonenhanced [[Computed tomography|CT]] (>20 HU)
* Increased attenuation on nonenhanced [[Computed tomography|CT]] (>20 HU)
* Increased [[mass]] vascularity
* Increased [[mass]] vascularity
Line 101:
Line 101:
** [[Fatigue]]
** [[Fatigue]]
** [[Weight loss]]
** [[Weight loss]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
**Irregular shape and inhomogeneous nature
**Irregular shape and inhomogeneous nature
**Tendency to be bilateral
**Tendency to be bilateral
Line 108:
Line 108:
**Isointensity or slightly less intense than the liver on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content)
**Isointensity or slightly less intense than the liver on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content)
**Elevated standardized uptake value on FDG-[[PET scan]]
**Elevated standardized uptake value on FDG-[[PET scan]]
|style="padding: 5px 5px; background: #F5F5F5;" |
|
|
|}
|}
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D [2]
Overview
Adrenal incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal adenoma , adrenocortical carcinoma , Cushing's syndrome , pheochromocytoma , and metastasis .
Differentiating different causese of Incidentaloma
Differential Diagnosis
Clinical picture
Imagings
Laboratory tests
Adrenal adenoma
Round and homogeneous density, smooth contour and sharp margination
Diameter less than 4 cm, unilateral location
Low unenhanced CT attenuation values (<10 HU)
Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
Isointensity with liver on both T1 and T2 weighted MRI sequences
Chemical shift : evidence of lipid on MRI
Cortisol level
Fasting serum cortisol at 8 AM following a 1 mg dose of dexamethasone at bedtime
Renin (PRA) or plasma renin concentration (PRC): very low in patients with primary aldosteronism, usually less than 1 ng/mL per hour for PRA and usually undetectable for PRCThe opening <ref>
tag is malformed or has a bad name
Adrenocortica l carcinoma
Irregular shape
Inhomogeneous density because of central areas of low attenuation due to tumor necrosis
Tumor calcification
Diameter usually >4 cm
Unilateral location
High unenhanced CT attenuation values (>20 HU)
Inhomogeneous enhancement on CT with intravenous contrast
Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
Hypointensity compared with liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI
High standardized uptake value (SUV) on FDG-PET-CT study
Evidence of local invasion or metastases
Cushing's syndrome
Imaging may show mass if presents
Pheochromocytoma
[null Insert paragraph]
Increased attenuation on nonenhanced CT (>20 HU)
Increased mass vascularity
Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
High signal intensity on T2 weighted MRI
Cystic and hemorrhagic changes
Variable size and may be bilateral
Adrenal metastasis
Irregular shape and inhomogeneous nature
Tendency to be bilateral
High unenhanced CT attenuation values (>20 HU) and enhancement with intravenous contrast on CT
Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
Isointensity or slightly less intense than the liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI (representing an increased water content)
Elevated standardized uptake value on FDG-PET scan
Differential diagnosis of Cushing's disease from other diseases
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause hypertensio n, hyperandrogenism , and obesity . Facial plethora , skin changes , osteoporosis , nephrolithiasis and neuropsychiatric conditions should raise the concern for Cushing's syndrome.[ 1] [ 2] [ 3] [ 4]
Differentiating pheochromocytoma from other diseases
Pheochromocytoma must be differentiated from other causes of paroxysmal hypertension . The differentials include:
Disease
Symptoms
Signs
Investigations
Pheochromocytoma
The symptoms of a pheochromocytoma are those of sympathetic nervous system hyperactivity and include:[1]
Pseudopheochromocytoma (idiopathic)[ 5] [ 6] [ 7] [ 8]
Paroxysmal activation of the sympathetic system causing:
Panic attacks
Laboratory studies that can exclude medical disorders other than panic disorder include:
Labile hypertension (White coat hypertension )
Elevated blood pressure , tachycardia , and may be anxiety in a clinical setting but not in other settings[1]
Hyperthyroidism
Renovascular hypertension
Stroke and compression of lateral medulla (Lateral medullary syndrome )
Difficulty sitting upright without support
Hypotonia of the ipsilateral arm
Ipsilateral decreased pain and temperature sensation in the face
The corneal reflex is usually reduced in the ipsilateral eye
Contralateral loss of pain and thermal sensation involving the body and limbs
Seizures
According to type; it may be focal or generalized, clinical or subclinical:[ 11]
Tonic-clonic seizure :
Repetitive twitches of arm and legs
Tongue bitting
Loss of consciousness
Symptoms occur suddenly and may persist
Muscle tension or tightening that causes twisting of the body, head, arms, or legs
Amnesia
Mood changes (fear, panic, or laughter)
Change in sensation of the skin over the arm, leg, or trunk
Vision changes and light flashes
Hallucinations
Tasting a bitter or metallic flavor
Complex partial seizure :
Confused or dazed and
Not be able to respond to questions or direction
Absence seizure :
Rapid blinking
Few seconds of staring into space
Carcinoid syndrome
Hypertensive crisis occurs with malignant carcinoid syndrome [ 14] . Symptoms include:
Migraine headaches
CT is indicated in patients with:[1] [2]
CT is not indicated in:
Drugs
Sympathomimetic drugs that can induce symptoms simulating pheochromocytoma include:
Baroreflex failure [ 22]
Baroreflex failure patients show a normal or even an increased pressor response to cold-pressor and handgrip testing. These responses are attenuated in patients with autonomic failure.
References
↑ Boscaro M, Barzon L, Fallo F, Sonino N (2001). "Cushing's syndrome". Lancet . 357 (9258): 783–91. doi :10.1016/S0140-6736(00)04172-6 . PMID 11253984 .
↑ Findling JW, Raff H (2001). "Diagnosis and differential diagnosis of Cushing's syndrome". Endocrinol. Metab. Clin. North Am . 30 (3): 729–47. PMID 11571938 .
↑ Newell-Price J, Trainer P, Besser M, Grossman A (1998). "The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states". Endocr. Rev . 19 (5): 647–72. doi :10.1210/edrv.19.5.0346 . PMID 9793762 .
↑ "How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH" .
↑ Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment" . Arch Intern Med . 159 (7): 670–4. PMID 10218745 .
↑ Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment" . Arch Intern Med . 159 (7): 670–4. PMID 10218745 .
↑ Mann SJ (1996). "Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions" . Psychosomatics . 37 (5): 444–50. doi :10.1016/S0033-3182(96)71532-3 . PMID 8824124 .
↑ Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF; et al. (2007). "Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma" . J Hypertens . 25 (11): 2286–95. doi :10.1097/HJH.0b013e3282ef5fac . PMID 17921824 .
↑ Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ (2005). "Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function" . Clin Endocrinol (Oxf) . 63 (1): 66–72. doi :10.1111/j.1365-2265.2005.02301.x . PMID 15963064 .
↑ Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment" . J Clin Endocrinol Metab . 73 (1): 146–50. doi :10.1210/jcem-73-1-146 . PMID 2045465 .
↑ 11.0 11.1 Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment" . J Clin Endocrinol Metab . 73 (1): 146–50. doi :10.1210/jcem-73-1-146 . PMID 2045465 .
↑ Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG; et al. (2012). "Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective" . Epilepsy Behav . 25 (2): 251–5. doi :10.1016/j.yebeh.2012.06.020 . PMID 23041172 .
↑ Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process (2011). "Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology" . Neurology . 76 (1): 94–9. doi :10.1212/WNL.0b013e318203e9d1 . PMID 21205698 .
↑ Warner RR, Mani S, Profeta J, Grunstein E (1994). "Octreotide treatment of carcinoid hypertensive crisis" . Mt Sinai J Med . 61 (4): 349–55. PMID 7969229 .
↑ Sjöblom SM (1988). "Clinical presentation and prognosis of gastrointestinal carcinoid tumours" . Scand J Gastroenterol . 23 (7): 779–87. PMID 3227292 .
↑ Feldman JM (1986). "Urinary serotonin in the diagnosis of carcinoid tumors" . Clin Chem . 32 (5): 840–4. PMID 2421946 .
↑ Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C; et al. (1990). "A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours" . Acta Endocrinol (Copenh) . 122 (2): 145–55. PMID 2316306 .
↑ Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society (2009). "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations" . Neuroendocrinology . 90 (2): 167–83. doi :10.1159/000184855 . PMID 19077417 .
↑ Kelman L (2004). "The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs" . Headache . 44 (9): 865–72. doi :10.1111/j.1526-4610.2004.04168.x . PMID 15447695 .
↑ Krentz AJ, Mikhail S, Cantrell P, Hill GM (2001). "Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine" . BMJ . 322 (7296): 1213. PMC 31620 . PMID 11358774 .
↑ Kuchel O (1985). "Pseudopheochromocytoma" . Hypertension . 7 (1): 151–8. PMID 3980057 .
↑ Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM (1993). "The diagnosis and treatment of baroreflex failure" . N Engl J Med . 329 (20): 1449–55. doi :10.1056/NEJM199311113292003 . PMID 8413455 .
↑ 23.0 23.1 Zar T, Peixoto AJ (2008). "Paroxysmal hypertension due to baroreflex failure" . Kidney Int . 74 (1): 126–31. doi :10.1038/ki.2008.30 . PMID 18322544 .
Template:WH
Template:WS